Skip to main content

Table 4 Nine potential risk factors were considered the association with incidence of HIV-1 DRMs among participants experiencing treatment failure

From: Prevalence of acquired drug resistance mutations in antiretroviral- experiencing subjects from 2012 to 2017 in Hunan Province of central South China

Variable

Mutation identified (n = 914)

No mutations identified (n = 1381)

OR

P

95%CI

Gender

 Male

654

994

0.95

0.68

0.76–1.20

 Female

260

387

1

  

Age

  < 14

20

12

1

  

 15~29

146

224

0.22

0.32

0.11–4.37

 30~44

314

461

0.21

0.31

0.01–4.22

 45~59

255

374

0.18

0.26

0.01–3.61

  ≥ 60

179

310

0.20

0.30

0.01–4.06

Regimen

 AZT + 3TC + NVP/EFV

468

424

1

  

 D4T + 3TC + NVP/EFV

102

62

1.39

0.10

0.94–2.05

 TDF + 3TC + NVP/EFV

287

396

0.40

0.00

0.32–0.51

 Second line regimens

57

499

0.08

0.00

0.06–0.11

Subtype

 AE

607

866

1

  

 BC

126

285

0.62

0.00

0.48–0.81

 B

103

160

0.80

0.16

0.59–1.09

 C

36

45

1.18

0.55

0.69–2.00

 Other

42

25

1.36

0.28

0.77–2.39

CD4 abs count (cells/mm3)

  ≤ 200

685

705

3.16

0.00

2.55–3.91

  > 200

229

676

1

1.00

 

WHO Stage

 I

449

695

1

  

 II

237

358

0.9

0.41

0.70–1.16

 III

129

214

0.81

0.20

0.59–1.12

 IV

99

114

1.08

0.68

0.74–1.59

Route of transmission

 BLOOD transmission

12

18

1

  

 PWID

79

148

1.02

0.96

0.42–2.50

 MSM

90

128

1.44

0.43

0.58–3.58

 Heterosexual

676

1024

1.27

0.58

0.55–2.95

 Vertical transmission

21

13

0.49

0.64

0.02–9.80

 Unknown

36

50

1.32

0.58

0.50–3.49

Recently 7 days number of doses missed

 0

369

866

1

  

  ≥ 1

545

515

2.94

0.00

2.38–3.63

Symptoms in recent three months

 No

  

1

  

 Yes

  

1.48

0.00

1.18–1.85

  1. Note: OR Odds ratio;
  2. CI Confidence interval
  3. P-Values in bold are statistically significant at the 0.05 significance level